ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Design and in Vitro Characterization of Highly sst2-Selective Somatostatin Antagonists Suitable for Radiotargeting

View Author Information
Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland, The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, California 92037, and Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
* To whom correspondence should be addressed. Phone: (858) 453-4100. Fax: (858) 552-1546. E-mail: [email protected]
†University of Berne.
#These authors contributed equally.
‡The Salk Institute for Biological Studies.
§University Hospital Basel.
Cite this: J. Med. Chem. 2008, 51, 13, 4030–4037
Publication Date (Web):June 11, 2008
Copyright © 2008 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    Radiolabeled sst2 and sst3 antagonists are better candidates for tumor targeting than agonists with comparable binding characteristics (Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Erchegyi, J.; Rivier, J.; Mäcke, H. R.; Reubi, J. C. Proc. Natl. Acad. Sci. U.S.A.2006, 103, 16436−16441.). Because most of the neuroendocrine tumors express sst2, we used the known antagonists acetyl-pNO2Phe2-c[dCys3-Tyr7-dTrp8-Lys9-Thr10-Cys14]-dTyr15-NH2 (1) (Bass, R. T.; Buckwalter, B. L.; Patel, B. P.; Pausch, M. H.; Price, L. A.; Strnad, J.; Hadcock, J. R. Mol. Pharmacol. 1996, 50, 709-715. Bass, R. T.; Buckwalter, B. L.; Patel, B. P.; Pausch, M. H.; Price, L. A.; Strnad, J.; Hadcock, J. R. Mol. Pharmacol. 1997, 51, 170; Erratum.) and H-Cpa2-c[dCys3-Tyr7-dTrp8-Lys9-Thr10-Cys14]-2Nal15-NH2 (7) (Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. J. Med. Chem. 1999, 42, 1863−1871.) as leads for analogues with increased sst2 binding affinity and selectivity. Among the 32 analogues reported here, DOTA-pNO2Phe2-c[dCys3-Tyr7-dAph8(Cbm)-Lys9-Thr10-Cys14-dTyr15-NH2 (3) and DOTA-Cpa2-c[dCys3-Aph7(Hor)-dAph8(Cbm)-Lys9-Thr10-Cys14]-dTyr15-NH2 (31) had the highest sst2 binding affinity and selectivity. All of the analogues tested kept their sst2 antagonistic properties (i.e., did not affect calcium release in vitro and competitively antagonized the agonistic effect of [Tyr3]octreotide). Moreover, in an immunofluorescence-based internalization assay, the new analogues prevented sst2 internalization induced by the sst2 agonist [Tyr3]octreotide without being active by themselves. In conclusion, several analogues (in particular 3, 31, and 32) have outstanding sst2 binding and functional antagonistic properties and, because of their DOTA moiety, are excellent candidates for in vivo targeting of sst2-expressing cancers.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    CZE profiles of selected compounds. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 92 publications.

    1. Martin Ullrich, Florian Brandt, Reik Löser, Jens Pietzsch, Robert Wodtke. Comparative Saturation Binding Analysis of 64Cu-Labeled Somatostatin Analogues Using Cell Homogenates and Intact Cells. ACS Omega 2023, 8 (26) , 24003-24009.
    2. Judit Erchegyi, Lixin Wang, Jozsef Gulyas, Manoj Samant, Marilyn H. Perrin, Kathy Lewis, Charleen Miller, Joan Vaughan, Cynthia Donaldson, Wolfgang Fischer, William Low, Seiichi Yakabi, Hiroshi Karasawa, Yvette Taché, Catherine Rivier, and Jean Rivier . Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins). Journal of Medicinal Chemistry 2016, 59 (3) , 854-866.
    3. Theodosia Maina, Renzo Cescato, Beatrice Waser, Aikaterini Tatsi, Aikaterini Kaloudi, Eric P. Krenning, Marion de Jong, Berthold A. Nock, and Jean Claude Reubi . [111In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. Journal of Medicinal Chemistry 2014, 57 (15) , 6564-6571.
    4. Judit Erchegyi, Renzo Cescato, Beatrice Waser, Jean E. Rivier, and Jean Claude Reubi . N-Imidazolebenzyl-histidine Substitution in Somatostatin and in Its Octapeptide Analogue Modulates Receptor Selectivity and Function. Journal of Medicinal Chemistry 2011, 54 (17) , 5981-5987.
    5. Carmen Wängler, Beatrice Waser, Andrea Alke, Ljuba Iovkova, Hans-Georg Buchholz, Sabrina Niedermoser, Klaus Jurkschat, Christian Fottner, Peter Bartenstein, Ralf Schirrmacher, Jean-Claude Reubi, Hans-Jürgen Wester, and Björn Wängler . One-Step 18F-Labeling of Carbohydrate-Conjugated Octreotate-Derivatives Containing a Silicon-Fluoride-Acceptor (SiFA): In Vitro and in Vivo Evaluation as Tumor Imaging Agents for Positron Emission Tomography (PET). Bioconjugate Chemistry 2010, 21 (12) , 2289-2296.
    6. Alessandra Di Cianni, Alfonso Carotenuto, Diego Brancaccio, Ettore Novellino, Jean Claude Reubi, Karin Beetschen, Anna Maria Papini and Mauro Ginanneschi . Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin Receptors. Journal of Medicinal Chemistry 2010, 53 (16) , 6188-6197.
    7. Seulki Lee, Jin Xie and Xiaoyuan Chen. Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis. Chemical Reviews 2010, 110 (5) , 3087-3111.
    8. Seulki Lee, Jin Xie and Xiaoyuan Chen. Peptide-Based Probes for Targeted Molecular Imaging. Biochemistry 2010, 49 (7) , 1364-1376.
    9. Judit Erchegyi, Renzo Cescato, Christy Rani R. Grace, Beatrice Waser, Véronique Piccand, Daniel Hoyer, Roland Riek, Jean E. Rivier and Jean Claude Reubi . Novel, Potent, and Radio-Iodinatable Somatostatin Receptor 1 (sst1) Selective Analogues. Journal of Medicinal Chemistry 2009, 52 (9) , 2733-2746.
    10. Eyup Akgün, Meike Körner, Fan Gao, Kaleeckal G. Harikumar, Beatrice Waser, Jean Claude Reubi, Philip S. Portoghese and Laurence J. Miller . Synthesis and in Vitro Characterization of Radioiodinatable Benzodiazepines Selective for Type 1 and Type 2 Cholecystokinin Receptors. Journal of Medicinal Chemistry 2009, 52 (7) , 2138-2147.
    11. Debby Feytens, Magali De Vlaeminck, Renzo Cescato, Dirk Tourwé and Jean Claude Reubi. Highly Potent 4-Amino-indolo[2,3-c]azepin-3-one-Containing Somatostatin Mimetics with a Range of sst Receptor Selectivities. Journal of Medicinal Chemistry 2009, 52 (1) , 95-104.
    12. Aikaterini Tatsi, Theodosia Maina, Beatrice Waser, Eric P. Krenning, Marion de Jong, Jean Claude Reubi, Paul Cordopatis, Berthold A. Nock. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile. International Journal of Molecular Sciences 2024, 25 (3) , 1921.
    13. Berthold A. Nock, Theodosia Maina. Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation. 2024, 207-224.
    14. Damian Wild. Theranostics with Somatostatin Receptor Antagonists. 2024, 349-359.
    15. Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille. First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs. EJNMMI Radiopharmacy and Chemistry 2023, 8 (1)
    16. Peipei Wang, Shuai Liu, Xiaojie Li, Xing Liu, Shaowu Li, Zhen Wu, Xin Cheng. The usefulness of [68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI. European Journal of Nuclear Medicine and Molecular Imaging 2023, 51 (1) , 218-225.
    17. Berthold A. Nock, Panagiotis Kanellopoulos, Lieke Joosten, Rosalba Mansi, Theodosia Maina. Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists. Pharmaceuticals 2023, 16 (5) , 674.
    18. Damian Wild, Melpomeni Fani. Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy. 2023, 335-348.
    19. Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Frontiers in Medicine 2022, 9
    20. Panagiotis Kanellopoulos, Berthold A. Nock, Lukas Greifenstein, Richard P. Baum, Frank Roesch, Theodosia Maina. [68Ga]Ga-DATA5m-LM4, a PET Radiotracer in the Diagnosis of SST2R-Positive Tumors: Preclinical and First Clinical Results. International Journal of Molecular Sciences 2022, 23 (23) , 14590.
    21. Wenli Zhao, Shuo Han, Na Qiu, Wenbo Feng, Mengjie Lu, Wenru Zhang, Mu Wang, Qingtong Zhou, Shutian Chen, Wei Xu, Juan Du, Xiaojing Chu, Cuiying Yi, Antao Dai, Liaoyuan Hu, Michelle Y. Shen, Yaping Sun, Qing Zhang, Yingli Ma, Wenge Zhong, Dehua Yang, Ming-Wei Wang, Beili Wu, Qiang Zhao. Structural insights into ligand recognition and selectivity of somatostatin receptors. Cell Research 2022, 32 (8) , 761-772.
    22. Wenjia Zhu, Ru Jia, Qiao Yang, Yuejuan Cheng, Hong Zhao, Chunmei Bai, Jianming Xu, Shaobo Yao, Li Huo. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging 2022, 49 (5) , 1613-1622.
    23. Melpomeni Fani, Rosalba Mansi, Guillaume P. Nicolas, Damian Wild. Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals. Cancers 2022, 14 (5) , 1172.
    24. Theodosia Maina, Berthold A. Nock. Peptide radiopharmaceuticals for targeted diagnosis & therapy of human tumors. 2022, 178-190.
    25. Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Müller, Helmut Mäcke. First-in-Humans Study of the SSTR Antagonist 177 Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. Journal of Nuclear Medicine 2021, 62 (11) , 1571-1581.
    26. Syed Faheem Askari Rizvi, Haixia Zhang. Emerging trends of receptor-mediated tumor targeting peptides: A review with perspective from molecular imaging modalities. European Journal of Medicinal Chemistry 2021, 221 , 113538.
    27. Qing Xie, Teli Liu, Jing Ding, Nina Zhou, Xiangxi Meng, Hua Zhu, Nan Li, Jiangyuan Yu, Zhi Yang. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging 2021, 48 (10) , 3129-3140.
    28. Camilla Bardram Johnbeck, Jann Mortensen. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. PET Clinics 2021, 16 (2) , 191-203.
    29. Fariba Maleki, Arezou Masteri Farahani, Farzaneh Rezazedeh, Nourollah Sadeghzadeh. Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging. Bioorganic Chemistry 2020, 99 , 103802.
    30. Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum. Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3. Clinical Nuclear Medicine 2020, 45 (3) , e165-e168.
    31. Hans-Jürgen Pietzsch, Constantin Mamat, Cristina Müller, Roger Schibli. Single Photon Emission Computed Tomography Tracer. 2020, 227-282.
    32. Hossein Behnammanesh, Safura Jokar, Mostafa Erfani, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Seyed Mohammad Mazidi, Maliheh Hajiramezanali, Davood Beiki. Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. Bioorganic Chemistry 2020, 94 , 103381.
    33. Rosalba Mansi, Melpomeni Fani. Design and development of the theranostic pair 177 Lu‐OPS201/ 68 Ga‐OPS202 for targeting somatostatin receptor expressing tumors. Journal of Labelled Compounds and Radiopharmaceuticals 2019, 62 (10) , 635-645.
    34. Lavinia Vija, Lawrence Dierickx, Frederic Courbon. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy. Annales d'Endocrinologie 2019, 80 (3) , 166-171.
    35. Lauren L. Radford, Dionysia Papagiannopoulou, Fabio Gallazzi, Ashley Berendzen, Lisa Watkinson, Terry Carmack, Michael R. Lewis, Silvia S. Jurisson, Heather M. Hennkens. Synthesis and evaluation of Re/99mTc(I) complexes bearing a somatostatin receptor-targeting antagonist and labeled via a novel [N,S,O] clickable bifunctional chelating agent. Bioorganic & Medicinal Chemistry 2019, 27 (3) , 492-501.
    36. Eleftherios Chatzellis, Gregory Kaltsas. Somatostatin Receptor Expression in Gastrointestinal Tumors. 2019, 587-596.
    37. Keelara Abiraj, Samer Ursillo, Maria Luisa Tamma, Svetlana N. Rylova, Beatrice Waser, Edwin C. Constable, Melpomeni Fani, Guillaume P. Nicolas, Jean Claude Reubi, Helmut R. Maecke. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. EJNMMI Research 2018, 8 (1)
    38. Thomas Günther, Giovanni Tulipano, Pascal Dournaud, Corinne Bousquet, Zsolt Csaba, Hans-Jürgen Kreienkamp, Amelie Lupp, Márta Korbonits, Justo P. Castaño, Hans-Jürgen Wester, Michael Culler, Shlomo Melmed, Stefan Schulz, . International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Reviews 2018, 70 (4) , 763-835.
    39. Guillaume P. Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Michael Lassmann, Jean Claude Reubi, Jean E.F. Rivier, Helmut R. Maecke, Melpomeni Fani, Damian Wild. Safety, Biodistribution, and Radiation Dosimetry of 68 Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine 2018, 59 (6) , 909-914.
    40. Svetlana N. Rylova, Christian Stoykow, Luigi Del Pozzo, Keelara Abiraj, Maria Luisa Tamma, Yvonne Kiefer, Melpomeni Fani, Helmut R. Maecke, . The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLOS ONE 2018, 13 (4) , e0195802.
    41. JinHong Jiang, WeiDong Jin, YaLi Peng, XueYa Liang, Shu Li, LiJuan Wei, ZhiPing Lei, LongFei Li, Min Chang. The role of Cortistatin-14 in the gastrointestinal motility in mice. Pharmacological Reports 2018, 70 (2) , 355-363.
    42. Subhani M. Okarvi, Helmut R. Maecke. Radiolabelled peptides in medical imaging. 2018, 431-483.
    43. Melpomeni Fani, Petra Peitl, Irina Velikyan. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals 2017, 10 (4) , 30.
    44. Guillaume P. Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani. Biodistribution, Pharmacokinetics, and Dosimetry of 177 Lu-, 90 Y-, and 111 In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177 Lu-DOTATATE: The Mass Effect. Journal of Nuclear Medicine 2017, 58 (9) , 1435-1441.
    45. Melpomeni Fani, Guillaume P. Nicolas, Damian Wild. Somatostatin Receptor Antagonists for Imaging and Therapy. Journal of Nuclear Medicine 2017, 58 (Supplement 2) , 61S-66S.
    46. Anna Tornesello, Luigi Buonaguro, Maria Tornesello, Franco Buonaguro. New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology. Molecules 2017, 22 (8) , 1282.
    47. Melpomeni Fani. Current and Future Radiopharmaceuticals in Neuroendocrine Tumor Imaging. 2017, 141-162.
    48. Subhani M. Okarvi, Helmut R. Maecke. Radiometallo-Labeled Peptides in Tumor Diagnosis and Targeted Radionuclide Therapy. 2016, 341-396.
    49. Tobias Baumann, Christof Rottenburger, Guillaume Nicolas, Damian Wild. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging. Best Practice & Research Clinical Endocrinology & Metabolism 2016, 30 (1) , 45-57.
    50. C. L. Charron, J. L. Hickey, T. K. Nsiama, D. R. Cruickshank, W. L. Turnbull, L. G. Luyt. Molecular imaging probes derived from natural peptides. Natural Product Reports 2016, 33 (6) , 761-800.
    51. Andreas Stengel, Hiroshi Karasawa, Yvette Taché. The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior. Hormones and Behavior 2015, 73 , 15-22.
    52. Talitha van der Meulen, Cynthia J Donaldson, Elena Cáceres, Anna E Hunter, Christopher Cowing-Zitron, Lynley D Pound, Michael W Adams, Andreas Zembrzycki, Kevin L Grove, Mark O Huising. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nature Medicine 2015, 21 (7) , 769-776.
    53. Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, Dik J. Kwekkeboom. Somatostatin Analogues and Radionuclides Used in Therapy. 2015, 214-229.
    54. Melpomeni Fani, Helmut R. Maecke. Radiolabeled Somatostatin Receptor Antagonists. 2015, 306-321.
    55. Agata Mulak, Muriel Larauche, Mandy Biraud, Mulugeta Million, Jean Rivier, Yvette Taché. Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice. Peptides 2015, 63 , 71-80.
    56. Hiroshi Karasawa, Seiichi Yakabi, Lixin Wang, Andreas Stengel, Jean Rivier, Yvette Taché. Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2014, 307 (7) , R793-R801.
    57. Hiroshi Karasawa, Seiichi Yakabi, Lixin Wang, Yvette Taché. Orexin-1 receptor mediates the increased food and water intake induced by intracerebroventricular injection of the stable somatostatin pan-agonist, ODT8-SST in rats. Neuroscience Letters 2014, 576 , 88-92.
    58. Aikaterini Tatsi, Theodosia Maina, Renzo Cescato, Beatrice Waser, Eric P. Krenning, Marion de Jong, Paul Cordopatis, Jean-Claude Reubi, Berthold A. Nock. [DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1–5 profile, stability and tumor targeting. European Journal of Medicinal Chemistry 2014, 73 , 30-37.
    59. Miriam Goebel-Stengel, Andreas Stengel, Lixin Wang, Yvette Taché. Orexigenic response to tail pinch: role of brain NPY 1 and corticotropin releasing factor receptors. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2014, 306 (3) , R164-R174.
    60. Frederic Fahey, Katherine Zukotynski, Jacek Capala, Nancy Knight, . Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. Journal of Nuclear Medicine 2014, 55 (2) , 337-348.
    61. Irina Velikyan. Radionuclides for Imaging and Therapy in Oncology. 2014, 285-325.
    62. Jean Claude Reubi, Agnes Schonbrunn. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends in Pharmacological Sciences 2013, 34 (12) , 676-688.
    63. Andreas Stengel, Jean Rivier, Yvette Taché. Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes. Peptides 2013, 42 , 70-77.
    64. Meike Körner, Jean Claude Reubi. Somatostatin/NPY. 2013, 548-555.
    65. Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Marion de Jong, Eric P. Krenning, Dik J. Kwekkeboom. Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy. Neuroendocrinology 2013, 97 (1) , 74-85.
    66. Cristina Müller, Roger Schibli. Single Photon Emission Computed Tomography Tracer. 2013, 65-105.
    67. Irina Velikyan. The Diversity of 68Ga-Based Imaging Agents. 2013, 101-131.
    68. Xuejuan Wang, Melpomeni Fani, Stefan Schulz, Jean Rivier, Jean Claude Reubi, Helmut R. Maecke. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2012, 39 (12) , 1876-1885.
    69. Melpomeni Fani, Friederike Braun, Beatrice Waser, Karin Beetschen, Renzo Cescato, Judit Erchegyi, Jean E. Rivier, Wolfgang A. Weber, Helmut R. Maecke, Jean Claude Reubi. Unexpected Sensitivity of sst 2 Antagonists to N-Terminal Radiometal Modifications. Journal of Nuclear Medicine 2012, 53 (9) , 1481-1489.
    70. Melpomeni Fani, Helmut R. Maecke. Radiopharmaceutical development of radiolabelled peptides. European Journal of Nuclear Medicine and Molecular Imaging 2012, 39 (S1) , 11-30.
    71. Aikaterini Tatsi, Theodosia Maina, Renzo Cescato, Beatrice Waser, Eric P Krenning, Marion de Jong, Paul Cordopatis, Jean Reubi, Berthold A Nock. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Research 2012, 2 (1) , 25.
    72. Renzo Cescato, Beatrice Waser, Melpomeni Fani, Jean Claude Reubi. Evaluation of 177 Lu-DOTA-sst 2 Antagonist Versus 177 Lu-DOTA-sst 2 Agonist Binding in Human Cancers In Vitro. Journal of Nuclear Medicine 2011, 52 (12) , 1886-1890.
    73. Andreas Stengel, Miriam Goebel-Stengel, Lixin Wang, Almaas Shaikh, Nils W. G. Lambrecht, Jean Rivier, Yvette Taché. Abdominal surgery inhibits circulating acyl ghrelin and ghrelin- O -acyltransferase levels in rats: role of the somatostatin receptor subtype 2. American Journal of Physiology-Gastrointestinal and Liver Physiology 2011, 301 (2) , G239-G248.
    74. Melpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, Rosalba Mansi, Maria Luisa Tamma, Renzo Cescato, Beatrice Waser, Wolfgang A. Weber, Jean Claude Reubi, Helmut R. Maecke. PET of Somatostatin Receptor–Positive Tumors Using 64 Cu- and 68 Ga-Somatostatin Antagonists: The Chelate Makes the Difference. Journal of Nuclear Medicine 2011, 52 (7) , 1110-1118.
    75. A. Stengel, M. Goebel-Stengel, L. Wang, M. Larauche, J. Rivier, Y. Taché. Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice. Neurogastroenterology & Motility 2011, 23 (6) , e223-e236.
    76. Helmut R. Maecke, Jean Claude Reubi. Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment. Journal of Nuclear Medicine 2011, 52 (6) , 841-844.
    77. Dieter Seebach, Aneta Lukaszuk, Krystyna Patora‐Komisarska, Dominika Podwysocka, James Gardiner, Marc‐Olivier Ebert, Jean Claude Reubi, Renzo Cescato, Beatrice Waser, Peter Gmeiner, Harald Hübner, Catherine Rougeot. On the Terminal Homologation of Physiologically Active Peptides as a Means of Increasing Stability in Human Serum – Neurotensin, Opiorphin, B27‐KK10 Epitope, NPY. Chemistry & Biodiversity 2011, 8 (5) , 711-739.
    78. Dongyu Gu, Ying Ma, Gang Niu, Yongjun Yan, Lixin Lang, Haji Akber Aisaand, Haokao Gao, Dale O. Kiesewetter, Xiaoyuan Chen. LC/MS evaluation of metabolism and membrane transport of bombesin peptides. Amino Acids 2011, 40 (2) , 669-675.
    79. Melpomeni Fani, Andreas Mueller, Maria-Luisa Tamma, Guillaume Nicolas, Hans R. Rink, Renzo Cescato, Jean Claude Reubi, Helmut R. Maecke. Radiolabeled Bicyclic Somatostatin-Based Analogs: A Novel Class of Potential Radiotracers for SPECT/PET of Neuroendocrine Tumors. Journal of Nuclear Medicine 2010, 51 (11) , 1771-1779.
    80. Beatrice Waser, Renzo Cescato, Maria-Luisa Tamma, Helmut R. Maecke, Jean Claude Reubi. Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. European Journal of Pharmacology 2010, 644 (1-3) , 257-262.
    81. Miriam Goebel, Andreas Stengel, Lixin Wang, Tamer Coskun, Jorge Alsina-Fernandez, Jean Rivier, Yvette Taché. Pattern of Fos expression in the brain induced by selective activation of somatostatin receptor 2 in rats. Brain Research 2010, 1351 , 150-164.
    82. Kjell E. Öberg, Jean–Claude Reubi, Dik J. Kwekkeboom, Eric P. Krenning. Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy. Gastroenterology 2010, 139 (3) , 742-753.e1.
    83. Andreas Stengel, Tamer Coskun, Miriam Goebel, Lixin Wang, Libbey Craft, Jorge Alsina-Fernandez, Jean Rivier, Yvette Taché. Central Injection of the Stable Somatostatin Analog ODT8-SST Induces a Somatostatin2 Receptor-Mediated Orexigenic Effect: Role of Neuropeptide Y and Opioid Signaling Pathways in Rats. Endocrinology 2010, 151 (9) , 4224-4235.
    84. Jean Claude Reubi, Judit Erchegyi, Renzo Cescato, Beatrice Waser, Jean E. Rivier. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. European Journal of Nuclear Medicine and Molecular Imaging 2010, 37 (8) , 1551-1558.
    85. Kai Chen, Peter S. Conti. Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews 2010, 62 (11) , 1005-1022.
    86. Prasant K Nanda, Stephanie R Lane, Lauren B Retzloff, Usha S Pandey, Charles Jeffrey Smith. Radiolabeled regulatory peptides for imaging and therapy. Current Opinion in Endocrinology, Diabetes and Obesity 2010, 17 (1) , 69-76.
    87. Renzo Cescato, Kimberly A. Loesch, Beatrice Waser, Helmut R. Mäcke, Jean E. Rivier, Jean Claude Reubi, Agnes Schonbrunn. Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways. Molecular Endocrinology 2010, 24 (1) , 240-249.
    88. Gábor Mező, Marilena Manea. Receptor-mediated tumor targeting based on peptide hormones. Expert Opinion on Drug Delivery 2010, 7 (1) , 79-96.
    89. Pavlos Msaouel, Evanthia Galanis, Michael Koutsilieris. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opinion on Investigational Drugs 2009, 18 (9) , 1297-1316.
    90. Margret Schottelius, Hans-Jürgen Wester. Molecular imaging targeting peptide receptors. Methods 2009, 48 (2) , 161-177.
    91. Jean Claude Reubi, Helmut R. Maecke. Peptide-Based Probes for Cancer Imaging. Journal of Nuclear Medicine 2008, 49 (11) , 1735-1738.
    92. Christy Rani R. Grace, Judit Erchegyi, Manoj Samant, Renzo Cescato, Veronique Piccand, Roland Riek, Jean Claude Reubi, Jean E. Rivier. Ring Size in Octreotide Amide Modulates Differently Agonist versus Antagonist Binding Affinity and Selectivity. Journal of Medicinal Chemistry 2008, 51 (9) , 2676-2681.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect